Stem Cell Sciences goes US
Wednesday, 04 March, 2009
Technology company Stem Cell Sciences (SCS) is to be sold to Delaware’s StemCells Inc for close to US$5 million.
SCS, which has a research laboratory in Melbourne and is headquartered in Cambridge in the UK, has an impressive portfolio of IP based around technologies for stem cell research including cell-based assays, gene delivery vehicles, cell media and methodologies.
In a statement, the companies said it was expected that SCS’s 20 full-time staff will be retained if the deal goes ahead. Agreement has already been received from 30 per cent of SCS shareholders.
An EGM to vote on the deal will be held in London on 27 March.
Specially designed peptides can treat complex diseases
Two separate research teams have found ways to create short chains of amino acids, termed...
Exposure to aircraft noise linked to poor heart function
People who live close to airports could be at greater risk of poor heart function, increasing the...
Predicting the impact of protein mutations with simple maths
Researchers have discovered that the impact of mutations on protein stability is more predictable...
